# Influenza during cancer treatment: antiviral prophylaxis after exposure and early treatment

Source: https://onco.cc/protocols/influenza-antiviral-prophylaxis-and-early-treatment/  
OnCo record `influenza-antiviral-prophylaxis-and-early-treatment` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Flu is more likely to become serious when cancer or its treatment has weakened the immune system. Antiviral medicines such as oseltamivir are meant to be started early, within 48 hours of the first symptoms or of close contact with flu. The NHS says to get urgent advice if you have flu symptoms and a weakened immune system. Tell your cancer team promptly if someone at home has flu.

## Summary

The guidelines read treat immunocompromised people with cancer as high risk and recommend an antiviral as early as possible. AGIHO 2025: as early as possible after symptom onset and diagnosis (AIIt), ideally within 48 hours. IDSA 2018: for documented or suspected influenza in immunocompromised outpatients (A-II) and in anyone hospitalised, regardless of illness duration (A-II). UKHSA 2026: oseltamivir first line for at-risk and severe cases, started before testing where no rapid test is available. CDC: decisions about starting treatment should not wait for laboratory confirmation. The licensed adult dose of oseltamivir is 75 mg twice daily for 5 days.

The 48-hour limit is the licensed one (NICE TA168 and the labels) and the guidelines do not apply it as a cut-off in this group. AGIHO says a late diagnosis should not preclude treatment in the severely immunocompromised. IDSA treats hospitalised people, and outpatients with severe or progressive illness, regardless of illness duration. UKHSA calls treatment beyond 48 hours off-label but possibly valuable up to 5 days from symptom onset in critical illness. Testing uses a molecular assay, and IDSA recommends testing immunocompromised people who have respiratory symptoms with or without fever (A-III), because their illness is frequently less characteristic.

Where they differ. Post-exposure prophylaxis: AGIHO recommends it for immunocompromised patients with cancer, ideally within 72 hours (BIIt); IDSA says clinicians can consider it for severely immunocompromised people in whom vaccination is contraindicated, unavailable or expected to work poorly (C-II), ideally no later than 48 hours after exposure, for 7 days (CDC also gives 7 days); UKHSA and NICE TA158 offer it to at-risk people, immunosuppression included, who are not adequately protected by vaccination, within 48 hours for oseltamivir or 36 hours for zanamivir, and UKHSA and the labels give 10 days; WHO 2024 gives a conditional recommendation for oseltamivir or baloxavir in people at extremely high risk. Treatment length: IDSA gives 5 days for uncomplicated influenza in otherwise healthy outpatients and says longer can be considered in immunocompromise (C-III); the European product information recommends 10 days in immunocompromised patients and UKHSA allows it; the US label gives 5 days and states that efficacy in immunocompromised patients has not been established. Kidney function: UKHSA 2026 keeps 75 mg twice daily down to a creatinine clearance of 31 mL/min, where the US label, CDC and the European product information reduce to 30 mg twice daily. Baloxavir: AGIHO gives it a lower grade than oseltamivir because it was not studied in patients with cancer; UKHSA reserves it; CDC does not recommend it as monotherapy in severely immunosuppressed people; WHO conditionally recommends it for non-severe influenza at high risk and recommends against oseltamivir for non-severe influenza; IDSA 2018 predates it. Season-long prophylaxis: IDSA allows it to be considered after stem cell transplant (B-II); NICE does not recommend it.

Resistance emerges more often in immunocompromised people (US label: 27% of influenza A/H1N1 infections in a treatment study, 32% in stem cell transplant recipients), and UKHSA advises considering repeat sampling and resistance testing when there is no response after 5 days. UKHSA reports that preliminary results of the REMAP-CAP trial in critically ill patients, with oseltamivir started a median of 5 days after symptoms began, showed no reduction in deaths and a higher death rate than with no antiviral, and that recruitment to those arms was stopped; it has kept oseltamivir first line while that evidence is reviewed, noting that the result may not apply to people treated earlier.

Your own team's protocol comes first, and local advice changes with the strains circulating each season. Vaccination of patients and their households is covered in the vaccination protocol.

## Fields

- Kind: Protocol
- Last checked: 2026-11-17
- Also known as: flu during chemotherapy; oseltamivir prophylaxis; Tamiflu after exposure; post-exposure prophylaxis for influenza; influenza chemoprophylaxis; flu antivirals in immunocompromised patients; baloxavir; neuraminidase inhibitors

## Connected records

- protocols: [Aciclovir prophylaxis against herpes simplex and shingles during cancer treatment](https://onco.cc/protocols/herpes-simplex-and-zoster-antiviral-prophylaxis/), [Hand hygiene in cancer care: staff, patients, families and visitors](https://onco.cc/protocols/hand-hygiene-in-cancer-care/), [Protective measures and daily life during neutropenia: hand hygiene, visitors, pets, plants, school and swimming](https://onco.cc/protocols/neutropenic-precautions-and-daily-life/), [Suspected febrile neutropenia (neutropenic sepsis): the first hour](https://onco.cc/protocols/febrile-neutropenia-first-hour/), [Vaccination before, during and after cancer treatment](https://onco.cc/protocols/vaccination-around-cancer-treatment/)
- technologies: [Allogeneic stem cell transplantation](https://onco.cc/technologies/allogeneic-hsct/)
- ideas: [Preventive oseltamivir after flu exposure compared with a ready supply for early treatment, in people on cancer treatment](https://onco.cc/ideas/idea-upgrade-influenza-post-exposure-prophylaxis-versus-early-treatment-in-cancer/)

---
JSON: https://onco.cc/api/v1/entities/influenza-antiviral-prophylaxis-and-early-treatment.json